PGK1 and benign prostatic hyperplasia: Terazosin, an α1 adrenergic receptor antagonist traditionally used for treating benign prostatic hyperplasia and occasional hypertension at higher dosages (above 10 mg daily), has recently been discovered to enhance ATP generation by regulating glycolysis through binding to PGK1 and augmenting its kinase activity.16